AC Immune

ACIUPhase 2

Lausanne, SwitzerlandFounded 2003acimmune.com

Founded in 2003 and publicly listed on NASDAQ, AC Immune is a global leader in developing precision diagnostics and therapeutics for neurodegenerative diseases. Its strategy is validated by high-value partnerships with pharmaceutical giants like Takeda, Eli Lilly, and Janssen, which have generated over CHF 450 million in funding. The company is advancing a broad pipeline focused on pathological proteins such as Abeta, Tau, alpha-synuclein, and TDP-43, aiming to slow or prevent disease progression.

Market Cap

$286.7M

Founded

2003

Employees

~150

Focus

BiologicsDiagnosticsSmall Molecules

AI Company Overview

Technology Platform

AC Immune's core technologies are the SupraAntigen® platform for designing best-in-class active immunotherapies and antibodies, and the Morphomer® platform for discovering brain-penetrant small molecules that inhibit pathological protein aggregation.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
Placebo + ACI-7104.056 at Dose A + ACI-7104.056 at Dose B (optional) + ACI-7104....	Parkinson Disease	Phase 2
ACI-24 + Placebo	Down Syndrome	Phase 2
Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-24.060 at Dose C + A...	Amyloid Plaque	Phase 1/2
ACI-35.030 + ACI-35.030 + ACI-35.030 + JACI-35.054 + JACI-35.054	Alzheimer's Disease	Phase 1/2
[18F]MNI-1216	Alpha-Synucleinopathy	Phase 1

Funding History

Total raised: $125M

PIPE$50MUndisclosedJun 15, 2020

IPO$60MUndisclosedSep 30, 2016

Series A$15MUndisclosedJun 15, 2003

Opportunities

The massive, growing unmet need in neurodegenerative diseases and the paradigm shift towards early intervention and prevention create a significant long-term market.

AC Immune's multi-target, multi-modality pipeline and precision medicine approach position it to capture value across Alzheimer's, Parkinson's, and rare neuro-orphan diseases as its programs advance.

Risk Factors

High risk of clinical failure inherent in neurodegenerative drug development; potential future dilution from equity fundraising; dependence on partners for key programs; intense competition from larger pharmaceutical companies and other biotechs; and regulatory uncertainty around novel endpoints for disease modification and prevention.

Competitive Landscape

AC Immune competes with large pharma (Biogen, Eisai, Roche) and biotechs (Prothena, Denali) in neurodegeneration. Its key differentiation is its integrated pipeline attacking multiple pathological proteins (Abeta, Tau, alpha-synuclein, TDP-43) with both therapeutics and diagnostics, powered by proprietary SupraAntigen® and Morphomer® platforms, validated by high-value partnerships.